Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Short-term Investments (2016 - 2025)

Iovance Biotherapeutics has reported Short-term Investments over the past 10 years, most recently at $133.9 million for Q4 2025.

  • Quarterly results put Short-term Investments at $133.9 million for Q4 2025, down 35.65% from a year ago — trailing twelve months through Dec 2025 was $133.9 million (down 35.65% YoY), and the annual figure for FY2025 was $133.9 million, down 35.65%.
  • Short-term Investments for Q4 2025 was $133.9 million at Iovance Biotherapeutics, down from $142.7 million in the prior quarter.
  • Over the last five years, Short-term Investments for IOVA hit a ceiling of $222.0 million in Q1 2024 and a floor of $20.9 million in Q2 2023.
  • Median Short-term Investments over the past 3 years was $153.8 million (2023), compared with a mean of $142.6 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 168.12% in 2024 and later plummeted 35.65% in 2025.
  • Iovance Biotherapeutics' Short-term Investments stood at $165.0 million in 2023, then increased by 26.13% to $208.1 million in 2024, then tumbled by 35.65% to $133.9 million in 2025.
  • The last three reported values for Short-term Investments were $133.9 million (Q4 2025), $142.7 million (Q3 2025), and $168.7 million (Q2 2025) per Business Quant data.